• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)

    2/14/24 4:21:51 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYT alert in real time by email
    SC 13G/A 1 tm242424d15_sc13ga.htm SC 13G/A

     

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Cyteir Therapeutics, Inc. 

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    23284P103

     

    (CUSIP Number)

     

    December 31, 2023

     
      (Date of Event which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.  23284P103

     

    1 NAMES OF REPORTING PERSONS  
    Baker Bros. Advisors LP 
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) ¨
    3 SEC USE ONLY 
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware 

      NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER  
    -0-
    6 SHARED VOTING POWER  
    -0-
    7 SOLE DISPOSITIVE POWER  
    -0-
    8 SHARED DISPOSITIVE POWER  
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    -0-
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions) 
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
    0.0% (1) 
    12 TYPE OF REPORTING PERSON (See Instructions)
    IA, PN 

     

     

     

     

    CUSIP No.  23284P103

     

    1 NAMES OF REPORTING PERSONS  
    Baker Bros. Advisors (GP) LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) ¨
    3 SEC USE ONLY 
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware 

      NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER  
    -0-
    6 SHARED VOTING POWER  
    -0-
    7 SOLE DISPOSITIVE POWER  
    -0-
    8 SHARED DISPOSITIVE POWER  
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    -0-
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions) 
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
    0.0% (1) 
    12 TYPE OF REPORTING PERSON (See Instructions)
    HC, OO

     

     

     

     

    CUSIP No.  23284P103 

     

    1 NAMES OF REPORTING PERSONS  
    Felix J. Baker
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) ¨
    3 SEC USE ONLY 
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States 

      NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER  
    -0-
    6 SHARED VOTING POWER  
    -0-
    7 SOLE DISPOSITIVE POWER  
    -0-
    8 SHARED DISPOSITIVE POWER  
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    -0-
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions) 
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
    0.0% 
    12 TYPE OF REPORTING PERSON (See Instructions)
    IN, HC

     

     

     

     

    CUSIP No.  23284P103

     

    1 NAMES OF REPORTING PERSONS  
    Julian C. Baker
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) ¨
    3 SEC USE ONLY 
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States 

      NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER  
    -0-
    6 SHARED VOTING POWER  
    -0-
    7 SOLE DISPOSITIVE POWER  
    -0-
    8 SHARED DISPOSITIVE POWER  
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    -0-
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions) 
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
    0.0% (1) 
    12 TYPE OF REPORTING PERSON (See Instructions)
    IN, HC

     

     

     

      

    Amendment No. 1 to Schedule 13G

     

    This Amendment No. 1 to Schedule 13G amends and restates the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a) Name of Issuer:

     

    Cyteir Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    99 Hayden Avenue, Building B, Suite 450

     

    Lexington, MA 02421

     

    Item 2(a) Name of Person Filing:

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons.

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c) Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”).

     

    Item 2(e) CUSIP Number:

     

    23284P103

     

     

     

     

    Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act.

     

      (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act.

     

      (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.

     

      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

     

      (e) ⌧ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

     

      (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

     

      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

      (i)  ¨   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

     

      (j) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. The Reporting Persons no longer beneficially own any securities of the Issuer.

     

    Name  Number of Shares of
    Common Stock
       Percent of
    Class 
    Outstanding
     
    667, L.P.   0    0.0%
    Baker Brothers Life Sciences, L.P.   0    0.0%
    Total   0    0.0%

     

     

     

     

    Pursuant to the management agreements, as amended, among the Adviser, 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Funds”) and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities previously held by the Funds, and thus the Adviser had complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to have been beneficial owners of securities of the Issuer directly held by the Funds.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ⌧.

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Item 8 Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024

     

     

    BAKER BROS. ADVISORS LP

     

    By: Baker Bros. Advisors (GP) LLC, its general partner

         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President
         
        /s/ Julian C. Baker
        Julian C. Baker
     
        /s/ Felix J. Baker
        Felix J. Baker

     

     

     

    Get the next $CYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYT

    DatePrice TargetRatingAnalyst
    2/7/2022$16.00Outperform
    Northland Capital
    7/13/2021$40.00Outperform
    Wedbush
    7/13/2021$33.00Overweight
    Morgan Stanley
    7/13/2021$23.00Buy
    B of A Securities
    7/13/2021$30.00Overweight
    JP Morgan
    More analyst ratings

    $CYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Leonard Braden Michael bought $503,238 worth of shares (170,589 units at $2.95) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/25/24 11:05:47 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leonard Braden Michael bought $342,469 worth of shares (113,777 units at $3.01) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/19/24 4:19:39 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Leonard Braden Michael claimed ownership of 3,704,687 shares (SEC Form 3)

    3 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/19/24 4:09:32 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on Cyteir Therapeutics with a new price target

    Northland Capital initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $16.00

    2/7/22 9:06:54 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Cyteir Therapeutics with a new price target

    Wedbush initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $40.00

    7/13/21 7:54:26 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Cyteir Therapeutics with a new price target

    Morgan Stanley initiated coverage of Cyteir Therapeutics with a rating of Overweight and set a new price target of $33.00

    7/13/21 7:33:21 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    SEC Filings

    View All

    SEC Form 15-12G filed by Cyteir Therapeutics Inc.

    15-12G - Cyteir Therapeutics, Inc. (0001662244) (Filer)

    3/29/24 6:11:57 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Cyteir Therapeutics Inc.

    S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)

    3/21/24 4:17:14 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Cyteir Therapeutics Inc.

    S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)

    3/21/24 4:17:45 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to

    3/7/24 4:30:00 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

    Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009 initial clinical data showed a promising response and differentiated safety profile R&D Day outlined near-term strategic priorities and highlighted breadth of Bicycle® platform technology and ability to develop highly differentiated precision therapies for cancer and other diseases Stephen Sands appointed to Board of Directors Cash and cash equivalents of $526.4 million as of December 31, 2023, expected to provide financial runway into 2026 Bi

    2/20/24 7:05:00 AM ET
    $BCYC
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

    - CYT-0851 demonstrated activity in combination with capecitabine in heavily pretreated platinum-refractory or -resistant ovarian cancer patients with a generally well tolerated safety profile - Overall disease control rate was 91% in the capecitabine combination with a median progression-free survival of 170 days Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination

    10/12/23 7:30:00 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Leonard Braden Michael bought $503,238 worth of shares (170,589 units at $2.95) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/25/24 11:05:47 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leonard Braden Michael bought $342,469 worth of shares (113,777 units at $3.01) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/19/24 4:19:39 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Financials

    Live finance-specific insights

    View All

    Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

    - Continue to enroll in monotherapy and combination studies with CYT-0851 with potential for interim safety and efficacy data in second half 2022 - Progress achieved in key clinical milestones described in the 2021 IPO: Advanced CYT-0851 monotherapy to Phase 2 and initiated Phase 1 combination therapy study - Projected cash runway into 2024 to support planned R&D and clinical studies - Conference call and webcast scheduled for 4:30 p.m. ET on March 16, 2022 Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the fourth quarter and full year

    3/16/22 4:01:00 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results. The live audio webcast can be accessed via the Investor Relations section of the Company's website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir's website for 30 days. About Cyteir Therapeutics, Inc. Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthet

    3/9/22 4:30:00 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)

    SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)

    3/19/24 4:29:26 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Cyteir Therapeutics Inc. (Amendment)

    SC 13D/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)

    3/12/24 4:16:28 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)

    SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)

    2/14/24 7:36:52 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Leadership Updates

    Live Leadership Updates

    View All

    Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice President of Regulatory Affairs and Quality. "Krisztina has an impressive track record of leading regulatory functions and development teams at global pharmaceutical companies to successful worldwide product registrations in oncology, demonstrating extensive knowledge of global clinical trial approval processes and requirements, strategic thinking about development plans that maximize the likelihood of successful regulatory appl

    5/3/22 9:00:00 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care